共 50 条
- [1] Dosing patterns and treatment patterns in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first lineJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)MacEwan, Joanna P.Silver, MichelleCockrum, PaulSanders, ChadKim, George P.
- [2] Adverse events in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first lineJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Kim, George P.Silver, MichelleSanders, ChadCockrum, PaulMacEwan, Joanna P.Duncan, Dan
- [3] Real-world overall survival and time to next treatment in patients with metastatic pancreatic ductal adenocarcinoma who received FOLFIRINOX and modified FOLFIRINOX in the first line.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 629 - 629Dennen, SyvartBoppudi Naga, Sai SritejaCockrum, PaulPaluri, Ravi Kumar
- [4] Adverse events in real-world patients covered by Medicare with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOXJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Dieguez, GabrielaTomicki, SamanthaCockrum, PaulHirsch, JaredBhatt, PrachiKim, George P.
- [5] Real-world treatment patterns and total cost of care in Medicare patients with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOXJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Hirsch, JaredCockrum, PaulTomicki, SamanthaDieguez, GabrielaBhatt, PrachiKim, George P.
- [6] Adverse events in real-world patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX (FFX) or gemcitabine with nab-paclitaxel (GnP) in the first line (1L)JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Dennen, SyvartSilver, MichelleCockrum, PaulPaluri, Ravi Kumar
- [7] Patterns of treatment switching and healthcare resource utilization differences among real-world Medicare patients with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOXJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Dieguez, GabrielaHirsch, JaredCockrum, PaulBhatt, PrachiTomicki, SamanthaKim, George P.
- [8] Components of total cost of care in real-world patients with mPDAC who received first-line FOLFIRINOX or Gem/AbraxJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Hirsch, JaredCockrum, PaulTomicki, SamanthaDieguez, GabrielaBhatt, PrachiKim, George P.
- [9] Are adverse events (AEs) during first-line FOLFIRINOX (FFX) more frequent in real-world (RW) patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who do not proceed to second-line therapy?JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 630 - 630Paluri, Ravi KumarSilver, MichelleCockrum, PaulDennen, Syvart
- [10] Real-world patterns of pain medication use among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)Laursen, Ashley AnnSurinach, AndyWang, ShuCockrum, PaulGeorge, Ben